Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (ASX: PBT) reports a capital raise event occurring in May 2013. The registrant is a biotechnology company focused on clinical trials for Huntington's Disease and Alzheimer's Disease. The filing discloses the issuance of new ordinary shares and the application for their quotation on the Australian Securities Exchange (ASX).
Key Financial Metrics and Capital Structure
- Securities Issued: 10,370,488 Ordinary Shares.
- Total Consideration Raised: $2,022,245 AUD.
- Issue Date: May 3, 2013.
- Post-Issue Capital: 381,610,426 Ordinary Shares quoted on ASX.
- Unquoted Securities: 34,852,725 unlisted options across various plans (PBTAB, PBTAI, PBTAM, etc.).
- Placement Capacity: The filing details remaining placement capacity under ASX rules, with 47,876,582 shares remaining under Rule 7.1 and 9,476,012 shares under Rule 7.1A.
Note: The filing does not provide revenue, profit, cash flow, or debt figures as it is a disclosure of a specific capital event rather than a periodic financial report.
Material Changes and Purpose of Issue
The primary material change is the increase in share capital by approximately 2.8% (10.37 million new shares against a pre-issue base of roughly 371 million). The proceeds from this issue are designated to fund and advance the development of the Company's key clinical asset, PBT2, which is currently in two concurrent clinical trials for Huntington's Disease and Alzheimer's Disease.
The securities were issued under an exception in ASX Listing Rule 7.2, following security holder approval obtained on December 12, 2012, under Rule 7.1A.
Outlook, Risks, and Management Commentary
Management commentary is limited to the strategic purpose of the capital raise: advancing clinical trials for PBT2. The filing includes standard warranties to the ASX that the issue complies with the law, is not for an illegal purpose, and that there is no "excluded information" required to be disclosed under the Corporations Act.
Risks and Contingencies: The filing notes that the quotation of additional securities is at the ASX's absolute discretion. The company warrants that no person has the right to return the securities under specific sections of the Corporations Act at the time of the request for quotation.
Investor Verification Checklist
- Verify the current status and progress of the PBT2 clinical trials for Huntington's and Alzheimer's Disease.
- Confirm the dilution impact of the 10,370,488 new shares on existing shareholders.
- Review the terms and expiry dates of the 34.85 million unlisted options to assess potential future dilution.
- Check subsequent filings to confirm the ASX granted quotation for the new shares.
- Monitor the company's cash runway given the capital-intensive nature of clinical development.